TriSalus Life Sciences, Inc.
TLSI
$5.10
$0.173.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 22.32% | 10.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.32% | 10.97% | |||
| Cost of Revenue | 20.54% | 22.94% | |||
| Gross Profit | 22.67% | 8.90% | |||
| SG&A Expenses | 9.53% | -12.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.42% | -6.18% | |||
| Operating Income | -0.04% | 21.38% | |||
| Income Before Tax | 20.05% | -2.58% | |||
| Income Tax Expenses | -160.00% | 600.00% | |||
| Earnings from Continuing Operations | 20.12% | -2.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.12% | -2.64% | |||
| EBIT | -0.04% | 21.38% | |||
| EBITDA | -0.14% | 21.60% | |||
| EPS Basic | 29.59% | 1.69% | |||
| Normalized Basic EPS | 18.36% | 16.32% | |||
| EPS Diluted | 29.59% | 1.69% | |||
| Normalized Diluted EPS | 18.36% | 16.32% | |||
| Average Basic Shares Outstanding | 15.32% | 3.54% | |||
| Average Diluted Shares Outstanding | 15.32% | 3.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||